- Home
- DXLG vs IMAB Comparison
DXLG vs IMAB Comparison
Compare DXLG & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXLG
- IMAB
- Stock Information
- Founded
- DXLG 1976
- IMAB 2014
- Country
- DXLG United States
- IMAB United States
- Employees
- DXLG N/A
- IMAB N/A
- Industry
- DXLG Clothing/Shoe/Accessory Stores
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DXLG Consumer Discretionary
- IMAB Health Care
- Exchange
- DXLG Nasdaq
- IMAB Nasdaq
- Market Cap
- DXLG 64.0M
- IMAB 73.9M
- IPO Year
- DXLG 1987
- IMAB 2020
- Fundamental
- Price
- DXLG $1.03
- IMAB $2.50
- Analyst Decision
- DXLG Strong Buy
- IMAB Strong Buy
- Analyst Count
- DXLG 1
- IMAB 2
- Target Price
- DXLG $2.50
- IMAB $5.50
- AVG Volume (30 Days)
- DXLG 270.8K
- IMAB 1.0M
- Earning Date
- DXLG 05-29-2025
- IMAB 05-15-2025
- Dividend Yield
- DXLG N/A
- IMAB N/A
- EPS Growth
- DXLG N/A
- IMAB N/A
- EPS
- DXLG N/A
- IMAB N/A
- Revenue
- DXLG $457,059,000.00
- IMAB N/A
- Revenue This Year
- DXLG N/A
- IMAB N/A
- Revenue Next Year
- DXLG $3.56
- IMAB N/A
- P/E Ratio
- DXLG N/A
- IMAB N/A
- Revenue Growth
- DXLG N/A
- IMAB N/A
- 52 Week Low
- DXLG $0.90
- IMAB $0.60
- 52 Week High
- DXLG $3.93
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- DXLG 43.76
- IMAB 67.42
- Support Level
- DXLG $1.00
- IMAB $2.29
- Resistance Level
- DXLG $1.16
- IMAB $2.69
- Average True Range (ATR)
- DXLG 0.08
- IMAB 0.35
- MACD
- DXLG -0.01
- IMAB 0.00
- Stochastic Oscillator
- DXLG 15.52
- IMAB 64.53
About DXLG Destination XL Group Inc.
Destination XL Group Inc is a retailer of branded and Tall men's clothing and shoes in the United States. It also sells products across the world. The company sells its products under the trade names Destination XL, DXL, DXL Men's Apparel, DXL outlets, Casual Male XL, and Casual Male XL outlets. The company has two principal operating segments: Store, and Direct business.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).